

# Celeste Lebbe

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5198160/publications.pdf>

Version: 2024-02-01

182  
papers

49,284  
citations

66250

44  
h-index

7836

155  
g-index

183  
all docs

183  
docs citations

183  
times ranked

40440  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinicopathologic and molecular characterization of melanomas mutated for CTNNB1 and MAPK. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 475-480.	1.4	6
2	Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. Journal of Clinical Oncology, 2022, 40, 127-137.	0.8	446
3	PD-1 blockade with pembrolizumab in classic or endemic Kaposi's sarcoma: a multicentre, single-arm, phase 2 study. Lancet Oncology, The, 2022, 23, 491-500.	5.1	20
4	The soluble form of CD160 acts as a tumor mediator of immune escape in melanoma. Cancer Immunology, Immunotherapy, 2022, 71, 2731-2742.	2.0	6
5	Sample CME Manuscript Submission "Response to Pham et al. "Review BRAF inhibition and the spectrum of granulomatous reactions". Journal of the American Academy of Dermatology, 2022, , .	0.6	1
6	IL-6 blockade in cancer patients treated with immune checkpoint blockade: A win-win strategy. Cancer Cell, 2022, 40, 450-451.	7.7	8
7	The role of stereotactic radiotherapy in addition to immunotherapy in the management of melanoma brain metastases: results of a systematic review. Radiologia Medica, 2022, 127, 773-783.	4.7	16
8	Phase II study SECOMBIT (sequential combo immuno and target therapy study): A subgroup analysis with a longer follow-up.. Journal of Clinical Oncology, 2022, 40, 9535-9535.	0.8	8
9	Abstract CT197: Phase Ib study of LXH254 + trametinib (TMT) in patients (pts) with <i>NRAS</i>-mutant melanoma. Cancer Research, 2022, 82, CT197-CT197.	0.4	0
10	Efficacy and tolerance of systemic therapies in metastatic melanoma of unknown primary versus known cutaneous: A multicenter retrospective study from the MelBase French Cohort.. Journal of Clinical Oncology, 2022, 40, 9556-9556.	0.8	0
11	Efficacy of ipilimumab 3mg/kg following progression on low dose ipilimumab in metastatic melanoma.. Journal of Clinical Oncology, 2022, 40, e21533-e21533.	0.8	0
12	Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline "Update 2022. European Journal of Cancer, 2022, 171, 203-231.	1.3	51
13	A randomized, controlled, open-label, phase 2 study of cemiplimab ± RP1 in patients with advanced cutaneous squamous cell carcinoma (CERPASS).. Journal of Clinical Oncology, 2022, 40, TPS9593-TPS9593.	0.8	0
14	Navtemadlin (KRT-232) activity after failure of anti-PD-1/L1 therapy in patients (pts) with <i>TP53<sup>WT</sup></i> Merkel cell carcinoma (MCC).. Journal of Clinical Oncology, 2022, 40, 9506-9506.	0.8	9
15	Efficacy and safety of "second adjuvant" therapy with BRAF/MEK inhibitors after resection of recurrent melanoma following adjuvant PD-1-based immunotherapy.. Journal of Clinical Oncology, 2022, 40, 9575-9575.	0.8	4
16	Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors. Targeted Oncology, 2021, 16, 37-46.	1.7	5
17	Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial. Targeted Oncology, 2021, 16, 47-57.	1.7	8
18	National early access programs and clinical trials: What opportunities for early access to therapeutic innovations for patients with malignant melanoma?. Cancer, 2021, 127, 2181-2183.	2.0	2

#	ARTICLE	IF	CITATIONS
19	Hematological immune related adverse events after treatment with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2021, 147, 170-181.	1.3	40
20	A Multicenter Phase II Study of Pazopanib in Patients with Unresectable Dermatofibrosarcoma Protuberans. <i>Journal of Investigative Dermatology</i> , 2021, 141, 761-769.e2.	0.3	7
21	Patterns and management of progression on first-line ipilimumab combined with anti-PD-1 (IPI+PD1) in metastatic melanoma (MM) patients.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9533-9533.	0.8	1
22	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 655-664.	5.1	37
23	Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders. , 2021, 9, e002121.		30
24	Two dosing regimens of nivolumab (NIVO) plus ipilimumab (IPI) for advanced (adv) melanoma: Three-year results of CheckMate 511.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9516-9516.	0.8	17
25	Durability of response to immune checkpoint inhibitors (ICI) in metastatic Merkel cell carcinoma (mMCC) after treatment cessation.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9543-9543.	0.8	2
26	Differential gradients of efficacy of immunotherapy according to the sun-exposure pattern of the site of occurrence of primary melanoma: A multicenter prospective cohort study (MELBASE).. <i>Journal of Clinical Oncology</i> , 2021, 39, e21545-e21545.	0.8	4
27	Impact of surgical margins on survival in cutaneous sarcomas: A nationwide study of French Sarcoma Group (FSG) from NETSARC Database.. <i>Journal of Clinical Oncology</i> , 2021, 39, e23537-e23537.	0.8	0
28	Phase II Open-Label Multicenter Study of Palbociclib + Vemurafenib in BRAF V600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism. <i>Clinical Cancer Research</i> , 2021, 27, 3876-3883.	3.2	8
29	Long-Term Outcome of Neoadjuvant Tyrosine Kinase Inhibitors Followed by Complete Surgery in Locally Advanced Dermatofibrosarcoma Protuberans. <i>Cancers</i> , 2021, 13, 2224.	1.7	8
30	Systemic Treatment Initiation in Classical and Endemic Kaposi's Sarcoma: Risk Factors and Global Multi-State Modelling in a Monocentric Cohort Study. <i>Cancers</i> , 2021, 13, 2519.	1.7	10
31	Case Report: Clinical Experience With Avelumab in Patients With Metastatic Merkel Cell Carcinoma and Brain Metastases Treated in Europe. <i>Frontiers in Oncology</i> , 2021, 11, 672021.	1.3	4
32	SARS-CoV-2 vaccines for cancer patients treated with immunotherapies: Recommendations from the French society for ImmunoTherapy of Cancer (FITC). <i>European Journal of Cancer</i> , 2021, 148, 121-123.	1.3	17
33	Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. <i>Lancet Oncology</i> , The, 2021, 22, 836-847.	5.1	104
34	The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis. <i>European Journal of Cancer</i> , 2021, 151, 72-83.	1.3	12
35	First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel) Tj ETQq1 1 0.784314 rgBT /Over		32
36	Successful rechallenge with avelumab in Merkel cell carcinoma. <i>European Journal of Cancer</i> , 2021, 153, 96-97.	1.3	2

#	ARTICLE	IF	CITATIONS
37	Real-world effectiveness of pembrolizumab in advanced melanoma: analysis of a French national clinicobiological database. <i>Immunotherapy</i> , 2021, 13, 905-916.	1.0	1
38	Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma – Authors' reply. <i>Lancet Oncology</i> , The, 2021, 22, e343-e344.	5.1	2
39	Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infection. <i>Science Advances</i> , 2021, 7, .	4.7	27
40	Outcome of pretransplant melanoma after solid organ transplantation: an observational study. <i>Transplant International</i> , 2021, 34, 2154-2165.	0.8	0
41	Immune Checkpoint Inhibitors in Transplantation – A Case Series and Comprehensive Review of Current Knowledge. <i>Transplantation</i> , 2021, 105, 67-78.	0.5	21
42	Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition – A Descriptive Observational Retrospective Multicenter Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 765608.	1.3	10
43	MAPK blockade, toxicities, pathogenesis and management. <i>Current Opinion in Oncology</i> , 2021, 33, 139-145.	1.1	3
44	Mitogen-activated protein kinase blockade in melanoma: intermittent versus continuous therapy, from preclinical to clinical data. <i>Current Opinion in Oncology</i> , 2021, 33, 127-132.	1.1	4
45	545 – A phase 2 study of retifanlimab in patients with advanced or metastatic merkel cell carcinoma (MCC) (POD1UM-201). , 2021, 9, A574-A575.		9
46	Positive Association Between Location of Melanoma, Ultraviolet Signature, Tumor Mutational Burden, and Response to Anti-PD-1 Therapy. <i>JCO Precision Oncology</i> , 2021, 5, 1821-1829.	1.5	17
47	Quality of life assessment in French patients with metastatic melanoma in real life. <i>Cancer</i> , 2020, 126, 611-618.	2.0	12
48	Intermittent Versus Continuous Dosing of MAPK Inhibitors in the Treatment of BRAF-Mutated Melanoma. <i>Translational Oncology</i> , 2020, 13, 275-286.	1.7	13
49	Targeted therapies in melanoma beyond BRAF: targeting NRAS-mutated and KIT-mutated melanoma. <i>Current Opinion in Oncology</i> , 2020, 32, 79-84.	1.1	25
50	Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials. <i>European Journal of Cancer</i> , 2020, 125, 114-120.	1.3	47
51	Epidemiology of Cutaneous T-Cell Lymphomas: A Systematic Review and Meta-Analysis of 16,953 Patients. <i>Cancers</i> , 2020, 12, 2921.	1.7	57
52	Five-Year Outcomes With Nivolumab in Patients With Wild-Type <i>BRAF</i> Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 3937-3946.	0.8	119
53	Progressive Desmoid Tumor: Radiomics Compared With Conventional Response Criteria for Predicting Progression During Systemic Therapy – A Multicenter Study by the French Sarcoma Group. <i>American Journal of Roentgenology</i> , 2020, 215, 1539-1548.	1.0	21
54	Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i. <i>Nature Medicine</i> , 2020, 26, 1557-1563.	15.2	78

#	ARTICLE	IF	CITATIONS
55	A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with BRAFV600E/K</i>-mutant Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 5102-5112.	3.2	23
56	Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover. <i>Cancers</i> , 2020, 12, 1727.	1.7	36
57	Reintroduction of immune-checkpoint inhibitors after immune-related meningitis: a case series of melanoma patients. , 2020, 8, e001034.		20
58	Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab. <i>Future Oncology</i> , 2020, 16, 2089-2099.	1.1	2
59	Impact of New Systemic Treatment and Radiotherapy in Melanoma Patients with Leptomeningeal Metastases. <i>Cancers</i> , 2020, 12, 2635.	1.7	5
60	Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program. , 2020, 8, e000313.		54
61	Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial. , 2020, 8, e000674.		132
62	Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma. , 2020, 8, e000391.		39
63	Patient Experiences with Avelumab in Treatment-Naïve Metastatic Merkel Cell Carcinoma: Longitudinal Qualitative Interview Findings from JAVELIN Merkel 200, a Registrational Clinical Trial. <i>Patient</i> , 2020, 13, 457-467.	1.1	11
64	Eosinophilic Fasciitis Triggered by Nivolumab: A Remarkable Efficacy of the mTOR Inhibitor Sirolimus. <i>Journal of Thoracic Oncology</i> , 2020, 15, e29-e30.	0.5	2
65	Combined Therapy with Anti-PD1 and BRAF and/or MEK Inhibitor for Advanced Melanoma: A Multicenter Cohort Study. <i>Cancers</i> , 2020, 12, 1666.	1.7	17
66	European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention. <i>European Journal of Cancer</i> , 2020, 128, 60-82.	1.3	131
67	European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment. <i>European Journal of Cancer</i> , 2020, 128, 83-102.	1.3	181
68	Deep cutaneous fungal infections in solid-organ transplant recipients. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 455-462.	0.6	11
69	Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 2476-2487.	0.8	152
70	Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy. , 2020, 8, e001689.		33
71	Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10005-10005.	0.8	26
72	The nature and management of acquired resistance to PD1-based therapy in melanoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10014-10014.	0.8	4

#	ARTICLE	IF	CITATIONS
73	The anti-PD-1 antibody spartalizumab in combination with dabrafenib and trametinib in advanced BRAF V600 mutant melanoma: Efficacy and safety findings from parts 1 and 2 of the Phase III COMBI-1 trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10028-10028.	0.8	8
74	Does body mass index really predict the response to systemic therapies in metastatic melanoma: A multicenter study from the MelBase French National Cohort?. <i>Journal of Clinical Oncology</i> , 2020, 38, 10031-10031.	0.8	1
75	Effect of first-line spartalizumab + dabrafenib + trametinib on immunosuppressive features detected in peripheral blood and clinical outcome in patients (pts) with advanced BRAF V600 mutant melanoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10034-10034.	0.8	2
76	Long-term immune-related adverse events under PD-1 inhibitors: a multicenter prospective cohort study (MELBASE).. <i>Journal of Clinical Oncology</i> , 2020, 38, 10057-10057.	0.8	3
77	The anti-PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600 mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-1.. <i>Journal of Clinical Oncology</i> , 2020, 38, 57-57.	0.8	7
78	Tumor microenvironment (TME), longitudinal biomarker changes, and clinical outcome in patients (pts) with advanced BRAF V600 mutant melanoma treated with first-line spartalizumab (S) + dabrafenib (D) + trametinib (T).. <i>Journal of Clinical Oncology</i> , 2020, 38, 39-39.	0.8	0
79	Combination anti-PD-1 and ipilimumab (ipi) therapy in patients with advanced melanoma and pre-existing autoimmune disorders (AD).. <i>Journal of Clinical Oncology</i> , 2020, 38, 10026-10026.	0.8	2
80	Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) induced by immune checkpoint inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e82-e82.	0.5	30
81	Pazopanib or methotrexate + vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study. <i>Lancet Oncology</i> , The, 2019, 20, 1263-1272.	5.1	123
82	Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2019, 381, 1535-1546.	13.9	2,484
83	Management of Kaposi sarcoma after solid organ transplantation: A European retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 448-455.	0.6	31
84	Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. <i>New England Journal of Medicine</i> , 2019, 381, 626-636.	13.9	909
85	Association of Time From Primary Diagnosis to First Distant Relapse of Metastatic Melanoma With Progression of Disease and Survival. <i>JAMA Dermatology</i> , 2019, 155, 673.	2.0	7
86	Rechallenge of immune checkpoint inhibitor after pembrolizumab-induced myasthenia gravis. <i>European Journal of Cancer</i> , 2019, 113, 72-74.	1.3	13
87	Impact of radiotherapy administered simultaneously with systemic treatment in patients with melanoma brain metastases within MelBase, a French multicentric prospective cohort. <i>European Journal of Cancer</i> , 2019, 112, 38-46.	1.3	27
88	Adverse events 2.0 Let us get SERIOs. <i>European Journal of Cancer</i> , 2019, 112, 29-31.	1.3	19
89	Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 867-875.	0.8	258
90	Successful Treatment of Generalized Eruptive Keratoacanthoma of Grzybowski with Acitretin. <i>Dermatology and Therapy</i> , 2019, 9, 383-388.	1.4	14

#	ARTICLE	IF	CITATIONS
91	Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 609-618.	2.0	21
92	New perspectives in Merkel cell carcinoma. <i>Current Opinion in Oncology</i> , 2019, 31, 72-83.	1.1	10
93	CD147 Is a Promising Target of Tumor Progression and a Prognostic Biomarker. <i>Cancers</i> , 2019, 11, 1803.	1.7	85
94	Severe gastrointestinal toxicity of MEK inhibitors. <i>Melanoma Research</i> , 2019, 29, 556-559.	0.6	13
95	Kaposi Sarcoma in HIV-positive Solid-Organ Transplant Recipients: A French Multicentric National Study and Literature Review. <i>Transplantation</i> , 2019, 103, e22-e28.	0.5	13
96	Management of immune-related adverse events resulting from immune checkpoint blockade. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 209-222.	1.1	20
97	Survival Outcomes in Patients With Previously Untreated <i>BRAF</i> Wild-Type Advanced Melanoma Treated With Nivolumab Therapy. <i>JAMA Oncology</i> , 2019, 5, 187.	3.4	295
98	Immune checkpoint inhibitor rechallenge in patients with immune-related myositis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e129-e129.	0.5	30
99	Ipilimumab versus placebo after complete resection of stage III melanoma: Long-term follow-up results the EORTC 18071 double-blind phase 3 randomized trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2512-2512.	0.8	18
100	Tumor microenvironment (TME), longitudinal biomarker changes, and clinical outcome in patients (pts) with advanced <i>BRAF</i> V600 mutant melanoma treated with first-line spartalizumab (S) + dabrafenib (D) + trametinib (T).. <i>Journal of Clinical Oncology</i> , 2019, 37, 9515-9515.	0.8	2
101	The anti-PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced <i>BRAF</i> V600 mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-3.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9531-9531.	0.8	31
102	Phase I-II open label multicenter study of PD0332991 in <i>BRAF</i> <sup>V600mut</sup> metastatic melanoma patients harboring <i>CDKN2A</i> loss and <i>RB1</i> expression and treated with vemurafenib.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9545-9545.	0.8	3
103	Express study: A trial in progress exploring the association between low level of genomic alteration and exceptional and unexpected response to targeted therapies in patients with solid tumors.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS3159-TPS3159.	0.8	0
104	Progression and hyperprogression after anti-PD1 therapy for unresectable stage III or IV melanoma patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, e21021-e21021.	0.8	0
105	Assessing cognitive function in patients treated with immune checkpoint inhibitors: A feasibility study. <i>Psycho-Oncology</i> , 2018, 27, 1861-1864.	1.0	12
106	Cutis laxa associated with monoclonal gammopathy: 14 new cases and review of the literature. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 945-947.	0.6	10
107	Benefit of the nivolumab and ipilimumab combination in pretreated advanced melanoma. <i>European Journal of Cancer</i> , 2018, 93, 147-149.	1.3	10
108	Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma. <i>JAMA Oncology</i> , 2018, 4, e180077.	3.4	304

#	ARTICLE	IF	CITATIONS
109	Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or) Tj ETQq1 1 0.784314 rgBT /Overlo 67, 1197-1208.	2.0	24
110	Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after a year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. , 2018, 6, 7.		263
111	Immune-related hepatitis with immunotherapy: Are corticosteroids always needed?. Journal of Hepatology, 2018, 69, 548-550.	1.8	71
112	Ipilimumab for the treatment of advanced melanoma in six kidney transplant patients. American Journal of Transplantation, 2018, 18, 3065-3071.	2.6	41
113	DESMOPAZ pazopanib (PZ) versus IV methotrexate/vinblastine (MV) in adult patients with progressive desmoid tumors (DT) a randomized phase II study from the French Sarcoma Group.. Journal of Clinical Oncology, 2018, 36, 11501-11501.	0.8	7
114	A multicenter phase II study of pazopanib in patients with unresectable or recurrent dermatofibrosarcoma protuberans (DFSP).. Journal of Clinical Oncology, 2018, 36, 11557-11557.	0.8	4
115	Nivolumab (Nivo) as neoadjuvant therapy in patients with resectable Merkel cell carcinoma (MCC) in CheckMate 358.. Journal of Clinical Oncology, 2018, 36, 9505-9505.	0.8	33
116	Ipilimumab combined with stereotactic radiosurgery in melanoma patients with brain metastases: A multicenter, open label, phase 2 trial.. Journal of Clinical Oncology, 2018, 36, 9520-9520.	0.8	3
117	Second-line avelumab treatment of patients (pts) with metastatic Merkel cell carcinoma (mMCC): Experience from a global expanded access program (EAP).. Journal of Clinical Oncology, 2018, 36, 9537-9537.	0.8	5
118	Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe. European Journal of Dermatology, 2018, 28, 736-749.	0.3	6
119	EGFR is involved in dermatofibrosarcoma protuberans progression to high grade sarcoma. Oncotarget, 2018, 9, 8478-8488.	0.8	8
120	Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries.. Journal of Clinical Oncology, 2018, 36, e18609-e18609.	0.8	0
121	Elderly patient's tolerance and efficacy for MAP-kinase inhibitors in a French melanoma real-life cohort.. Journal of Clinical Oncology, 2018, 36, e21536-e21536.	0.8	0
122	Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. Journal of Clinical Oncology, 2017, 35, 226-235.	0.8	458
123	Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. Lancet Oncology, The, 2017, 18, 393-403.	5.1	91
124	Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome induced by nivolumab. Seminars in Arthritis and Rheumatism, 2017, 47, 281-287.	1.6	42
125	Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. European Journal of Cancer, 2017, 82, 45-55.	1.3	160
126	Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncology, The, 2017, 18, 863-873.	5.1	561



#	ARTICLE	IF	CITATIONS
127	Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 611-622.	5.1	428
128	Merkel cell carcinoma: Epidemiology, prognosis, therapy and unmet medical needs. <i>European Journal of Cancer</i> , 2017, 71, 53-69.	1.3	307
129	Merkel cell carcinoma. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17077.	18.1	393
130	Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma. <i>European Journal of Cancer</i> , 2017, 86, 115-124.	1.3	76
131	Transient pituitary ACTH-dependent Cushing syndrome caused by an immune checkpoint inhibitor combination. <i>Melanoma Research</i> , 2017, 27, 649-652.	0.6	33
132	Outcome of second kidney transplantation in patients with previous post-transplantation Kaposi's sarcoma: A French retrospective study. <i>Clinical Transplantation</i> , 2017, 31, e13091.	0.8	4
133	Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1824-1835.	13.9	1,752
134	Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1345-1356.	13.9	3,589
135	Survival After Fulminant Myocarditis Induced by Immune-Checkpoint Inhibitors. <i>Annals of Internal Medicine</i> , 2017, 167, 683.	2.0	60
136	Mechanisms Underpinning Increased Plasma Creatinine Levels in Patients Receiving Vemurafenib for Advanced Melanoma. <i>PLoS ONE</i> , 2016, 11, e0149873.	1.1	29
137	Pigmented Bowen's disease presenting with a "starburst" pattern. <i>Dermatology Practical and Conceptual</i> , 2016, 6, 47-49.	0.5	2
138	Anti-PD1-induced collagenous colitis in a melanoma patient. <i>Melanoma Research</i> , 2016, 26, 308-311.	0.6	86
139	ZEB1-mediated melanoma cell plasticity enhances resistance to MAPK inhibitors. <i>EMBO Molecular Medicine</i> , 2016, 8, 1143-1161.	3.3	98
140	Association of Vemurafenib and Pipobroman Enhances BRAF-CRAF Dimerization in Squamous Cell Carcinoma. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1302-1305.	0.3	1
141	Treatment patterns of advanced malignant melanoma (stage III-IV) – A review of current standards in Europe. <i>European Journal of Cancer</i> , 2016, 60, 179-189.	1.3	47
142	Nivolumab-Induced Sarcoid-Like Granulomatous Reaction in a Patient With Advanced Melanoma. <i>Chest</i> , 2016, 149, e133-e136.	0.4	142
143	Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1374-1385.	5.1	1,034
144	Relevance of serum biomarkers associated with melanoma during follow-up of anti-CTLA-4 immunotherapy. <i>International Immunopharmacology</i> , 2016, 40, 466-473.	1.7	25

#	ARTICLE	IF	CITATIONS
145	Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. <i>New England Journal of Medicine</i> , 2016, 375, 1845-1855.	13.9	1,140
146	Usual type vulvar intraepithelial neoplasia: report of a case and its dermoscopic features. <i>International Journal of Dermatology</i> , 2016, 55, e621-e623.	0.5	4
147	Ipilimumab reshapes T cell memory subsets in melanoma patients with clinical response. <i>OncoImmunology</i> , 2016, 5, 1136045.	2.1	22
148	Improved sarcoma management in a national network of reference centers: Analysis of the NetSarc network on 13,454 patients treated between 2010 and 2014.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11013-11013.	0.8	10
149	Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic Merkel cell carcinoma previously treated with chemotherapy: Results of the phase 2 JAVELIN Merkel 200 trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9508-9508.	0.8	9
150	Immunotherapy-treated melanoma brain metastases within the French national cohort, MelBase.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9556-9556.	0.8	2
151	Bayesian individual exposure estimation of dabrafenib alone or in combination with trametinib in mutated-BRAF V600E metastatic melanoma patients.. <i>Journal of Clinical Oncology</i> , 2016, 34, e14105-e14105.	0.8	0
152	Melapred: first susceptibility test to sporadic melanoma in daily dermatological practice.. <i>Journal of Clinical Oncology</i> , 2016, 34, e21056-e21056.	0.8	0
153	Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. <i>Lancet, The</i> , 2015, 386, 444-451.	6.3	1,175
154	Nivolumab in Previously Untreated Melanoma without BRAF Mutation. <i>New England Journal of Medicine</i> , 2015, 372, 320-330.	13.9	4,795
155	Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. <i>European Journal of Cancer</i> , 2015, 51, 833-840.	1.3	71
156	Single-center study under a French Temporary Authorization for Use (TAU) protocol for ipilimumab in metastatic melanoma: negative impact of baseline corticosteroids. <i>European Journal of Dermatology</i> , 2015, 25, 36-44.	0.3	35
157	Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline. <i>European Journal of Cancer</i> , 2015, 51, 2396-2403.	1.3	320
158	Overall survival in COMBI-d, a randomized, double-blinded, phase III study comparing the combination of dabrafenib and trametinib with dabrafenib and placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/Kmutation-positive cutaneous melanoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 102-102.	0.8	3
159	A phase Ib/II study of BRAF inhibitor (BRAFi) encorafenib (ENCO) plus MEK inhibitor (MEKi) binimetinib (BINI) in cutaneous melanoma patients naive to BRAFi treatment.. <i>Journal of Clinical Oncology</i> , 2015, 33, 9007-9007.	0.8	39
160	Prognostic value of BRAF <sup>V600</sup> mutations in American Joint Committee on Cancer (AJCC) stage 3 cutaneous melanoma patients in the MelanCohort prospective cohort.. <i>Journal of Clinical Oncology</i> , 2015, 33, 9037-9037.	0.8	1
161	Low vemurafenib plasma exposure as a short-term predictive parameter of progression disease in metastatic BRAF <sup>V600</sup> mut melanoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 9072-9072.	0.8	1
162	EMMPRIN/CD147 as a novel independent prognostic biomarker in melanoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, e20027-e20027.	0.8	2

#	ARTICLE	IF	CITATIONS
163	Phase II multicentric uncontrolled national trial assessing the efficacy of nilotinib in the treatment of advanced melanomas with c-KIT mutation or amplification: Results of the pharmacodynamic study.. Journal of Clinical Oncology, 2015, 33, e20062-e20062.	0.8	1
164	A randomized, open label, multicenter comparative phase II trial of ipilimumab after isolated limb perfusion (ILP), versus ILP alone in patients with in-transit metastases melanoma stage IIIB and IIIC.. Journal of Clinical Oncology, 2015, 33, e20107-e20107.	0.8	0
165	Mechanisms of elevated serum creatinine in patients receiving vemurafenib for advanced melanoma.. Journal of Clinical Oncology, 2015, 33, e20022-e20022.	0.8	0
166	First-in-human phase I study of the DNA repair inhibitor DT01 in combination with radiotherapy in patients with in transit melanoma.. Journal of Clinical Oncology, 2015, 33, 2555-2555.	0.8	0
167	Follow-up of a French national cohort of melanoma stage IV and unresectable stage III patients, MelBase.. Journal of Clinical Oncology, 2015, 33, e20113-e20113.	0.8	0
168	TGF- $\beta$ 2-Induced (TGFBI) Protein in Melanoma: A Signature of High Metastatic Potential. Journal of Investigative Dermatology, 2014, 134, 1675-1685.	0.3	37
169	Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer Treatment Reviews, 2014, 40, 1056-1064.	3.4	178
170	BRAF V600 mutation levels predict response to vemurafenib in metastatic melanoma. Melanoma Research, 2014, 24, 415-418.	0.6	22
171	Ipilimumab-induced acute severe colitis treated by infliximab. Melanoma Research, 2013, 23, 227-230.	0.6	117
172	Personal melanoma risk awareness versus intrinsic risk.. Journal of Clinical Oncology, 2013, 31, 9069-9069.	0.8	0
173	Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment. Health and Quality of Life Outcomes, 2012, 10, 66.	1.0	55
174	Sun exposure profile in the French population: Results of the EDIFICE melanoma survey.. Journal of Clinical Oncology, 2012, 30, 1566-1566.	0.8	1
175	Comparison of sun protection modalities in parents and children.. Journal of Clinical Oncology, 2012, 30, 8601-8601.	0.8	1
176	Nuclear Medicine in Early-Stage Melanoma: Sentinel Node Biopsy <sup>18</sup> F-FDG-PET/CT. PET Clinics, 2011, 6, 9-25.	1.5	6
177	Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma. New England Journal of Medicine, 2011, 364, 2517-2526.	13.9	4,074
178	Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. New England Journal of Medicine, 2011, 364, 2507-2516.	13.9	6,976
179	Imatinib Mesylate as a Preoperative Therapy in Dermatofibrosarcoma: Results of a Multicenter Phase II Study on 25 Patients. Clinical Cancer Research, 2010, 16, 3288-3295.	3.2	128
180	Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. New England Journal of Medicine, 2010, 363, 711-723.	13.9	13,065

#	ARTICLE	IF	CITATIONS
181	Human Herpesvirus 8. <i>Cancer Treatment and Research</i> , 2009, 146, 169-188.	0.2	3
182	Infliximab for hidradenitis suppurativa: report of seven consecutive patients. <i>Experimental Dermatology</i> , 2008, 15, 482-482.	1.4	1